학술논문

The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update.
Document Type
Article
Source
Critical Reviews in Clinical Laboratory Sciences. Mar2020, Vol. 57 Issue 2, p114-125. 12p. 2 Diagrams.
Subject
*DRUG therapy for heart diseases
*HEART disease prognosis
*BIOMARKERS
*CHRONIC diseases
*CYTOKINES
*FAT cells
*GENES
*INFLAMMATORY mediators
*MACROPHAGES
*PEPTIDE hormones
*TRANSFORMING growth factors-beta
*OXIDATIVE stress
*ANGIOTENSIN receptors
*TROPONIN
Language
ISSN
1040-8363
Abstract
Growth differentiation factor-15 (GDF-15), also known as macrophage inhibitory cytokine-1 (MIC-1) or non-steroidal anti-inflammatory drug-activated gene (NAG-1) has been identified as a biomarker of response to treatment and prognosis in cardiovascular diseases. GDF-15 is a member of the transforming growth factor-β superfamily and is involved in several pathological conditions such as inflammation, cancer, cardiovascular, pulmonary and renal diseases. Cardiac myocytes produce and secrete GDF-15 in response to oxidative stress, stimulation with angiotensin II or proinflammatory cytokines, ischemia, and mechanical stretch. Other cellular sources of GDF-15 production are macrophages, vascular smooth muscle cells, endothelial cells, and adipocytes, which secrete GDF-15 in response to oxidative or metabolic stress or stimulation of proinflammatory cytokines. GDF-15 is induced in hypertrophic and dilated cardiomyopathy after volume overload, ischemia, and heart failure. GDF-15 can be used as a marker of prognosis in patients with cardiovascular disorders, in combination with conventional prognostic factors, such as N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT). [ABSTRACT FROM AUTHOR]